Effimune SAS

Effimune SAS

Effimune SA, a biotechnology company, engages in the discovery and development of therapeutic molecules, antibodies, and therapies for auto-immune diseases and transplantation. It specializes in the research and development of immunomodulators in autoimmunity and transplantation. The company’s solutions include FR104, a monovalent pegylated Fab antibody antagonist of the CD28 that blocks effector T cell responses and amplifies Treg responses; MD707, a monoclonal antibody that depletes effector T lymphocytes without altering Treg; and MP196, a monoclonal antibody that specifically neutralizes IL-23, a cytokine implied in various auto-immune diseases, such as rheumatoid arthritis, Crohn’s disease, and multiple sclerosis. Its drugs regulate the immune system in organ and tissue transplantation, and auto-immune disease.